Search - tctmd.com

Displaying 1 - 20 of 48

Sort: Relevancy | Date

News Daily News

Side Effects of Statins Might Be Overstated: CTT Collaboration

Michael O'Riordan

February 12, 2026

News Opinion CV Team Dispatch

January 2026 Dispatch for the CV Team

L.A. McKeown

January 16, 2026

News Daily News

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

Caitlin E. Cox

July 14, 2025

News Daily News

Coverage and Use of Impella and Watchman: A Tale of Four Countries

Michael O'Riordan

March 04, 2025

News Opinion CV Team Dispatch

June 2024 Dispatch for the CV Team

L.A. McKeown

June 01, 2024

News Daily News

FDA Approves Bioresorbable Scaffold for BTK Lesions

Michael O'Riordan

April 29, 2024

News Daily News

FDA Approves TriClip TEER Device for Tricuspid Repair

L.A. McKeown

April 02, 2024

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

News Daily News

FDA Approves First Transcatheter Tricuspid Valve Replacement Device

L.A. McKeown

February 02, 2024

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Daily News

Symplicity Spyral Approved: FDA Clears Second Renal Denervation System

Todd Neale

November 20, 2023

News Daily News

FDA Approves Paradise Renal Denervation System: What Comes Next?

Todd Neale

November 08, 2023

News Daily News

FDA Approves Blood Flow-Diverting LimFlow System for No-Option CLTI

L.A. McKeown

September 12, 2023

News Daily News

FDA Approves Colchicine for Decreasing CV Events

Caitlin E. Cox

June 20, 2023

News Daily News

FDA Grants First HF Indication for IV Iron to Ferric Carboxymaltose

Shelley Wood

June 05, 2023

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Conference News TVT 2022

Non-COAPT-Like Patients Fare Well With MitraClip, EXPAND Suggests

Michael O'Riordan

June 09, 2022

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

News Daily News

FDA Clears SAPIEN 3 With Alterra Prestent for Pulmonary Valve Replacement

L.A. McKeown

December 20, 2021

Advertisement

Side Effects of Statins Might Be Overstated: CTT Collaboration

January 2026 Dispatch for the CV Team

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

Coverage and Use of Impella and Watchman: A Tale of Four Countries

June 2024 Dispatch for the CV Team

FDA Approves Bioresorbable Scaffold for BTK Lesions

FDA Approves TriClip TEER Device for Tricuspid Repair

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

FDA Approves First Transcatheter Tricuspid Valve Replacement Device

Top Endovascular News of 2023

Symplicity Spyral Approved: FDA Clears Second Renal Denervation System

FDA Approves Paradise Renal Denervation System: What Comes Next?

FDA Approves Blood Flow-Diverting LimFlow System for No-Option CLTI

FDA Approves Colchicine for Decreasing CV Events

FDA Grants First HF Indication for IV Iron to Ferric Carboxymaltose

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Non-COAPT-Like Patients Fare Well With MitraClip, EXPAND Suggests

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

FDA Clears SAPIEN 3 With Alterra Prestent for Pulmonary Valve Replacement

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content